幼年期脑室内注射高剂量3,3',5-三碘甲状腺乙酸改善MCT8缺陷小鼠模型的外周甲状腺功能亢进并在有限脑区介导甲状腺模拟效应
在MCT8缺陷(Mct8-/y与Dio2-/-双基因敲除)小鼠模型中,幼年期每日脑室内注射400 ng/g体重的TRIAC可改善外周甲状腺功能亢进,不加重脑甲状腺功能减退,增加多个脑区TRIAC含量,但仅在有限脑区观察到轻度甲状腺模拟活性。
要点
- 幼年期脑室内注射高剂量TRIAC可改善MCT8缺陷小鼠的外周甲状腺功能亢进。
- 该治疗不进一步加重脑甲状腺功能减退,并增加多个脑区TRIAC含量。
- 仅有限脑区观察到轻度甲状腺模拟活性,作者认为脑内效应极小。
核心结论
- 在MCT8缺陷小鼠模型中,幼年期脑室内给予高剂量TRIAC可有效使外周甲状腺功能亢进正常化,但在脑内仅产生极小的甲状腺模拟活性。
研究设计与样本
- 在Mct8-/y与脱碘酶2(Dio2)-/-双基因敲除MCT8缺陷小鼠模型中,每日脑室内注射400 ng/g体重的TRIAC。
- 采用放射免疫分析法测定血液和组织中甲状腺激素与TRIAC水平,采用实时定量聚合酶链反应评估外周和中枢组织中甲状腺激素调节基因的表达。
主要发现
- 脑室内给予高剂量TRIAC改善了外周甲状腺功能亢进。
- 在脑内,该治疗未进一步加重脑甲状腺功能减退,并增加了多个脑区的TRIAC含量。
- 仅在有限脑区观察到轻度的甲状腺模拟活性。
临床怎么用
- 作者认为在MCT8缺陷小鼠模型幼年期通过脑室内途径给予高剂量TRIAC可有效使外周甲状腺功能亢进正常化,但脑内甲状腺模拟活性极小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Patients lacking functional monocarboxylate transporter 8 (MCT8), a highly specific thyroid hormone (TH) transporter, present severe psychomotor disabilities. MCT8 deficiency leads to peripheral hyperthyroidism and brain hypothyroidism, the latter due to impaired transport of TH across brain barriers. Available treatments for patients are limited and aim to overcome the limited TH transport across brain barriers. The use of TH analogues such as 3,3',5-triiodothyroacetic acid (TRIAC) that do not require MCT8 to cross the cellular membranes is considered a potential therapy for MCT8 deficiency. Previous studies have shown that systemic administration of TRIAC at therapeutic doses does not increase TRIAC content in the brain, while intracerebroventricular (ICV) administration of therapeutic doses of TRIAC increases TRIAC content in the brain but does not mediate thyromimetic effects. In view of this, we hypothesize that ICV administration of high doses of TRIAC can mediate thyromimetic effects in the brain without worsening the brain hypothyroidism or peripheral hyperthyroidism of patients. Methods: We administered 400 ng/g of body weight per day of ICV TRIAC in a mouse model of MCT8 deficiency: Mct8-/y and deiodinase 2 (Dio2)-/- double knockout mice. The effects of this treatment on TH and TRIAC levels/content in blood and tissues were determined by radioimmunoassay and effects on TH-regulated genes were assessed by real time-quantitative polymerase chain reaction in peripheral and central tissues. Results: ICV administration of high doses of TRIAC ameliorated the peripheral hyperthyroidism. In the brain, this treatment did not further aggravate brain hypothyroidism and increased TRIAC content in several brain regions; however, only moderate thyromimetic activity was observed in restricted brain areas. Conclusion: Administration of high doses of TRIAC by ICV delivery at juvenile stages in a mouse model of MCT8 deficiency is effective in normalizing peripheral hyperthyroidism but exerts minimal thyromimetic activity in the brain.
引用
- Grijota-Martínez C, Montero-Pedrazuela A, Hidalgo-Álvarez J, et al. Intracerebroventricular High Doses of 3,3',5-Triiodothyroacetic Acid at Juvenile Stages Improve Peripheral Hyperthyroidism and Mediate Thyromimetic Effects in Limited Brain Regions in a Mouse Model of Monocarboxylate Transporter 8 Deficiency. Thyroid. 2023. PMID: 36565029. doi:10.1089/thy.2022.0562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。